In vivo investigations on the clinical specimens from CAD patients demonstrated that Smad2 is highly activated in ECs of atherosclerotic lesions, which is accompanied by the concomitant increase of FN rather than LM expression in lesions. This evidence concerns the gene SMAD2 and coronary artery disorder.